BRISTOL, Tenn.--(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC announced today the results of a multicenter, randomized, vehicle-controlled study recently published in the June 2008 issue of the Journal of Pediatrics. The study demonstrated that Atopiclair (MAS063DP) cream is effective and safe as a monotherapy for the treatment of symptoms of mild to moderate atopic dermatitis (eczema or AD) in infants and children.
